Viatris Inc
VTRSAPI behind this page
VTRS Q1 2026 request
Playground key active
/api/financials?ticker=VTRS&year=2026&quarter=1
Pick an endpoint and run the request.Income Statement
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Revenue | 3,509.7 | 3,243.2 | +8.2% |
Show Product Lines breakouts |
|||
| Amitiza ® | 34 | 33.3 | +2.1% |
| Brands | 2,332.5 | 2,116.9 | +10.2% |
| Brands · Developed Markets Segment | 1,069 | 1,019.8 | +4.8% |
| Brands · Emerging Markets Segment | 447.2 | 402.5 | +11.1% |
| Brands · Greater China | 677.2 | 552.8 | +22.5% |
| Brands · Japan, Australia and New Zealand Segment | 139.1 | 141.8 | -1.9% |
| Celebrex ® | 67.1 | 63.4 | +5.8% |
| Creon ® | 97.4 | 82.4 | +18.2% |
| Dymista ® | 37.3 | 42.8 | -12.9% |
| Effexor ® | 62 | 59.3 | +4.6% |
| EpiPen® Auto-Injectors | 101.1 | 96.7 | +4.6% |
| Generics | 1,177.2 | 1,126.3 | +4.5% |
| Generics · Developed Markets Segment | 951.8 | 871.9 | +9.2% |
| Generics · Emerging Markets Segment | 88.2 | 117.4 | -24.9% |
| Generics · Greater China | 2.9 | 2.7 | +7.4% |
| Generics · Japan, Australia and New Zealand Segment | 134.3 | 134.3 | 0.0% |
| Lipitor | 462 | 388 | +19.1% |
| Lyrica ® | 120.6 | 112.6 | +7.1% |
| Norvasc | 210 | 172.3 | +21.9% |
| Viagra ® | 95 | 98.5 | -3.6% |
| Xalabrands | 39.2 | 37.1 | +5.7% |
| Xanax ® | 34.8 | 32.3 | +7.7% |
| Yupelri ® | 62.5 | 58.3 | +7.2% |
| Zoloft ® | 72.6 | 60.2 | +20.6% |
Show Business Segments breakouts |
|||
| Developed Markets Segment · Operating Segments | 2,020.8 | 1,891.7 | +6.8% |
| Emerging Markets Segment · Operating Segments | 535.4 | 519.9 | +3.0% |
| Greater China · Operating Segments | 680.1 | 555.5 | +22.4% |
| Japan, Australia and New Zealand Segment · Operating Segments | 273.4 | 276.1 | -1.0% |
| Other Revenue | 7.3 | 11.1 | -34.2% |
Show Product Lines breakouts |
|||
| Product And Service Other · Developed Markets Segment | 5.2 | 6.9 | -24.6% |
| Product And Service Other · Emerging Markets Segment | 2 | 3.2 | -37.5% |
| Product And Service Other · Japan, Australia and New Zealand Segment | 0.1 | 1 | -90.0% |
| Revenue | 3,517 | 3,254.3 | +8.1% |
Show Business Segments breakouts |
|||
| Developed Markets Segment | 2,026 | 1,898.6 | +6.7% |
| Emerging Markets Segment | 537.4 | 523.1 | +2.7% |
| Greater China | 680.1 | 555.5 | +22.4% |
| Japan, Australia and New Zealand Segment | 273.5 | 277.1 | -1.3% |
| Cost of Revenue | 2,359.8 | 2,093.1 | +12.7% |
| Gross Profit | 1,157.2 | 1,161.2 | -0.3% |
| Research & Development | 248.6 | 222 | +12.0% |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | 248.6 | 222 | +12.0% |
| Other Research And Development Expense Refund | 6 | 10 | -40.0% |
| Selling, General & Administrative | 928.8 | 948.1 | -2.0% |
| Gain Loss Related To Litigation Settlement | 53.5 | -73.5 | +172.8% |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | 53.5 | -73.5 | +172.8% |
| Operating Expenses | 1,236.9 | 4,043.4 | -69.4% |
| Operating Income | -79.7 | -2,882.2 | +97.2% |
Show Business Segments breakouts |
|||
| Developed Markets Segment · Operating Segments | 780.8 | 738.1 | +5.8% |
| Emerging Markets Segment · Operating Segments | 246.7 | 236 | +4.5% |
| Greater China · Operating Segments | 497.3 | 384.7 | +29.3% |
| Japan, Australia and New Zealand Segment · Operating Segments | 64.7 | 62.2 | +4.0% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 1,589.5 | 1,421 | +11.9% |
| Interest Expense | 120.1 | 115.5 | +4.0% |
| Other Non-Operating Income (Expense) | 47.5 | 99.3 | -52.2% |
| Income Before Taxes | -247.3 | -3,097 | +92.0% |
| Income Tax Expense (Benefit) | -423.7 | -55 | -670.4% |
| Net Income Loss Available To Common Stockholders Basic | 176.4 | -3,042 | +105.8% |
| EPS (Basic) | 0.15 | -2.55 | +105.9% |
| EPS (Diluted) | 0.15 | -2.55 | +105.9% |
| Wtd Avg Shares (Basic) | 1,155.4 | 1,192.4 | -3.1% |
| Wtd Avg Shares (Diluted) | 1,175.3 | 1,192.4 | -1.4% |
| Comprehensive Income | 83.6 | -2,700 | +103.1% |
| Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax (Q) | — | — | — |
Show Derivative Risk breakouts |
|||
| Foreign Exchange Contract · Cash Flow Hedging | 1.6 | -13.2 | +112.1% |
| Foreign Exchange Contract · Net Investment Hedging | -3.4 | — | — |
| Foreign Exchange Contract · Nondesignated | 32.7 | -116.4 | +128.1% |
| Interest Rate Swap · Cash Flow Hedging | -0.9 | -0.9 | 0.0% |
| Interest Rate Swap · Net Investment Hedging | 9.7 | -19.8 | +149.0% |
Balance Sheet
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 1,804.2 | 755 | +139.0% |
| Accounts Receivable | 3,076.3 | 3,125.7 | -1.6% |
Show Accounts Notes Loans And Financing Receivable By Receivable Type breakouts |
|||
| Variable Consideration | 2,200.4 | 2,516.7 | -12.6% |
| Inventory | 3,927 | 4,096.4 | -4.1% |
| Prepaid Expenses & Other Current Assets | 2,109.3 | 1,645.3 | +28.2% |
| Total Current Assets | 10,916.8 | 9,622.4 | +13.5% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 2,527.9 | 2,635.6 | -4.1% |
| Goodwill | 6,692.4 | — | — |
Show Business Segments breakouts |
|||
| Developed Markets Segment | 4,961.7 | — | — |
| Emerging Markets Segment | 795.3 | — | — |
| Greater China | 935.4 | — | — |
| Deferred Tax Assets | 1,109.2 | 817.6 | +35.7% |
| Other Non-Current Assets | 1,106 | 2,274.9 | -51.4% |
| Total Assets | 36,834.6 | 38,474.9 | -4.3% |
| Operating Lease Right-of-Use Assets | 253 | 265.9 | -4.9% |
| Intangible Assets | 13,776.3 | 15,857.9 | -13.1% |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 14,482.3 | 16,662.3 | -13.1% |
| Current Liabilities | |||
| Accounts Payable Trade Current | 1,749.4 | 1,988.4 | -12.0% |
| Current Portion of Long-Term Debt | 1,931.1 | 8.5 | +22618.8% |
| Other Liabilities Current | 3,129.8 | 3,629.8 | -13.8% |
| Total Current Liabilities | 6,810.3 | 5,720.1 | +19.1% |
| Debt Current | 1,927.6 | — | — |
Show Debt Instrument breakouts |
|||
| Other Current Portion of Long-term Debt | 1.1 | — | — |
| YEN Term Loan | 252 | — | — |
| Non-Current Liabilities | |||
| Long-Term Debt | 12,413.5 | 14,177.5 | -12.4% |
Show Debt Instrument breakouts |
|||
| 2028 Euro Senior Notes · Senior Notes | 864.2 | 808.4 | +6.9% |
| 2028 Senior Notes [Member] · Senior Notes | 749.6 | 749.3 | 0.0% |
| 2043 Senior Notes (5.400% coupon) · Senior Notes | 497.6 | 497.6 | 0.0% |
| 2046 Senior Notes (5.250% coupon) · Senior Notes | 999.9 | 999.9 | 0.0% |
| 2048 Senior Notes [Member] · Senior Notes | 747.9 | 747.9 | 0.0% |
| Other Long Term Debt [Member] | 3.1 | 2.2 | +40.9% |
| Deferred Tax Liabilities | 870.6 | 1,082.5 | -19.6% |
| Other Non-Current Liabilities | 2,082.5 | 1,844.4 | +12.9% |
| Total Liabilities | 22,176.9 | 22,824.5 | -2.8% |
| Long-Term Debt (Q) | — | — | — |
Show Debt Instrument breakouts |
|||
| 2027 Euro Senior Notes · Net Investment Hedging | 850 | 850 | 0.0% |
| 2027 Euro Senior Notes · Senior Notes | 992.7 | 937.5 | +5.9% |
| 2027 Senior Notes · Senior Notes | 757.1 | 762.8 | -0.7% |
| 2028 Euro Senior Notes · Net Investment Hedging | 750 | 750 | 0.0% |
| 2030 Senior Notes · Senior Notes | 1,486.7 | 1,494.9 | -0.5% |
| 2032 Euro Senior Notes · Net Investment Hedging | 1,250 | 1,250 | 0.0% |
| 2032 Euro Senior Notes · Senior Notes | 1,520.8 | 1,434.9 | +6.0% |
| 2040 Senior Notes · Senior Notes | 1,628.3 | 1,635.4 | -0.4% |
| 2050 Senior Notes · Senior Notes | 2,185.6 | 2,190.4 | -0.2% |
| YEN Term Loan · Net Investment Hedging | 40,000 | 40,000 | 0.0% |
Show Derivative Instruments Gain Loss By Hedging Relationship breakouts |
|||
| Net Investment Hedging | 2,850 | 2,850 | 0.0% |
| Operating Lease Liabilities | 167.2 | 177.1 | -5.6% |
| Stockholders' Equity | |||
| Common Stock | 12.6 | 12.4 | +1.6% |
| Additional Paid-In Capital | 18,663.9 | 18,960.8 | -1.6% |
| Retained Earnings | -211.9 | 227.9 | -193.0% |
| Accumulated Other Comprehensive Income | -2,799.8 | -2,870.9 | +2.5% |
| Stockholders Equity Parent Before Treasury Stock | 15,664.8 | 16,330.2 | -4.1% |
| Treasury Stock Value | 1,007.1 | 679.8 | +48.1% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 14,657.7 | 15,650.4 | -6.3% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -2,799.8 | -2,870.9 | +2.5% |
| Additional Paid In Capital | 18,663.9 | 18,960.8 | -1.6% |
| Common Stock | 12.6 | 12.4 | +1.6% |
| Retained Earnings | -211.9 | 227.9 | -193.0% |
| Total Liabilities & Equity | 36,834.6 | 38,474.9 | -4.3% |
| Total Stockholders' Equity (Q) | — | — | — |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | 277.8 | 253.8 | +9.5% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | 2.1 | 9 | -76.7% |
| Accumulated Net Unrealized Investment Gain Loss | -0.8 | -0.8 | 0.0% |
| Accumulated Other Comprehensive Income | -2,799.8 | -2,870.9 | +2.5% |
| Accumulated Translation Adjustment | -3,221.8 | -3,492 | +7.7% |
| Aoci Derivative Qualifying As Hedge Excluded Component Parent | 142.9 | 359.1 | -60.2% |
Cash Flow Statement
| Metric | YTD Q1 2026 | YTD Q1 2025 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 676.1 | 664.7 | +1.7% |
| Stock-Based Compensation | 48.2 | 55.2 | -12.7% |
| Deferred Income Taxes | -69.7 | -43.6 | -59.9% |
| Gain Loss On Sale Of Business | 13.9 | 36.9 | -62.3% |
Show Disposal Group Classification breakouts |
|||
| Disposal Group Held For Sale Or Disposed Of By Sale Not Discontinued Operations | 13.9 | 36.9 | -62.3% |
| Payments To Acquire In Process Research And Development Other | 6 | 15 | -60.0% |
| Other Non-Cash Items | 182.3 | 203.8 | -10.5% |
| Changeinnoncashlitigationsettlementsnet | 58 | -69.4 | +183.6% |
| Change in Accounts Receivable | -126.3 | 168 | -175.2% |
| Change in Inventory | -123 | -193.7 | +36.5% |
| Increase Decrease In Accounts Payable Trade | 32.7 | 101.6 | -67.8% |
| Increase Decrease In Accrued Income Taxes Payable | -463.4 | -120.6 | -284.2% |
| Increase Decrease In Other Operating Capital Net | -22.9 | -177.2 | +87.1% |
| Net Cash from Operations | 388.3 | 535.5 | -27.5% |
| Investing Activities | |||
| Proceeds From Sale Of Equity Securities Fv Ni | 400 | — | — |
| Capital Expenditures | -39.9 | -42.6 | +6.3% |
| Payments To Acquire Marketable Securities | -7.5 | -4.6 | -63.0% |
| Proceeds From Sale And Maturity Of Marketable Securities | 7.5 | 4.6 | +63.0% |
| Other Investing Activities | -82 | -18.8 | -336.2% |
| Proceeds From Refund Of In Process Research And Development | -2.3 | -15 | +84.7% |
| Proceeds From Sale Of Productive Assets | 1.6 | 11.3 | -85.8% |
| Net Cash from Investing | 277.4 | -65.1 | +526.1% |
| Financing Activities | |||
| Tax Withholding for Share Compensation | -56.5 | -29.3 | -92.8% |
| Payments Of Merger Related Costs Financing Activities | -7.9 | -11.4 | +30.7% |
| Payments To Minority Shareholders | -139.6 | -143.3 | +2.6% |
| Proceeds From Issuance Of Common Stock | 0.5 | 0.6 | -16.7% |
| Proceeds From Payments For Other Financing Activities | -0.3 | -109.6 | +99.7% |
| Net Cash from Financing | -203.8 | -467 | +56.4% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | -4.2 | 16.8 | -125.0% |
| Net Change in Cash | 457.7 | 20.2 | +2165.8% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 1,805.7 | 756.3 | +138.8% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.